Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Tizanidine Tablets

Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.

Completed Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-180-15 D-0223-2024
Class II · Moderate risk

Premier Value Tussin Cough DM

CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Ongoing Microbial contamination Seaway Pharma Inc. D-0215-2024
Class II · Moderate risk

Good Neighbor Pharmacy

MICROBIAL CONTAMINATION OF NON-STERILE PRODUCTS - Presence of Acetobacter nitrogenifigens bacteria.

Ongoing Microbial contamination Pharma Nobis LLC NDC 46122-741-38 D-0227-2024
Class II · Moderate risk

Tacrolimus Capsules

Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Nystatin 150 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk

Nystatin 2 Bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk

Nystatin 500 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-3 D-0155-2024
Class II · Moderate risk

Nystatin 5bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-5 D-0154-2024

Recalls by year